http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113018421-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 |
| filingDate | 2021-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113018421-B |
| titleOfInvention | Use of cholesterol-25-hydroxylase and enzymatic product thereof in the manufacture of a medicament for inhibiting a novel coronavirus |
| abstract | The invention belongs to the field of chemical medicines, and relates to application of cholesterol-25-hydroxylase and an enzymatic product thereof in preparing a medicine for inhibiting novel coronavirus. In vitro cell experiments, either over-expression of cholesterol-25-hydroxylase (CH25H) or administration of synthetic 25-hydroxycholesterol (25HC) can well inhibit SARS-CoV-2 infection with good safety, and both can be used for preparing medicines for inhibiting SARS-CoV-2. |
| priorityDate | 2020-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 210.